Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment Score: 65/100

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company...

Key Takeaway: Jazz Pharmaceuticals has announced its participation in Citi's 2024 Global Healthcare Conference, scheduled for December 3, 2024. Company management will engage in a fireside chat, accessible via audio webcast. This event will allow investors to gain insights into the company's strategies and developments. Jazz remains committed to advancing treatments for serious diseases through its diverse portfolio and innovative pipelines.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jazz Pharmaceuticals will participate in Citi's prestigious 2024 Global Healthcare Conference.
  • Management's engagement in the fireside chat highlights their commitment to transparency with investors.
  • The company is focusing on innovations to transform the lives of patients, indicating a strong mission.

Full Press Release Details

DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024 , at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT .
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations . A replay of the webcast will be archived on the website for 30 days.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Investors: Andrea N. Flynn , Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717
Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc

21 %

Frequently Asked Questions

When will Jazz Pharmaceuticals participate in the Citi conference?

Jazz Pharmaceuticals will join the Citi Global Healthcare Conference on December 3, 2024.

How can I access the Jazz Pharmaceuticals webcast?

The webcast will be available in the Investors section of Jazz's website.

What is the focus of Jazz Pharmaceuticals?

Jazz Pharmaceuticals aims to develop life-changing medicines for serious diseases.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

What types of treatments does Jazz Pharmaceuticals offer?

Jazz provides therapies for sleep disorders, epilepsy, and cancer treatments.

Last updated: Nov 19, 2024